Fundraising FoxMPM BioImpact — 2021 Investments
4 investments dated 2021 · listed companies and verified rows first · show all
Entrada Therapeutics is a biotech company developing intracellular therapeutics based on its proprietary EEV Platform, aimed at reaching previously inaccessible or undruggable disease-causing targets inside cells.
BiotechHealthtechBoston, US
Natarajan Sethuraman(Executive Officer)inNerissa Kreher(Executive Officer)inKory Wentworth(Executive Officer)inDipal Doshi(Chief Executive Officer)inNatarajan Sethuraman, PhD(President of Research and Development)Nathan J. Dowden(President and Chief Operating Officer)in
Board seatTodd Foley· per SEC Form D
Co-investors5AM VenturesAgent CapitalMRL Ventures FundRoche Venture FundTCG CrossoverWellington Management
Umoja Biopharma develops in vivo CAR T cell cancer therapies using its VivoVec platform, which generates chimeric antigen receptor T cells directly inside a patient's body rather than through the traditional ex vivo process.
BiotechHealthtechSeattle, US
Andrew M. Scharenberg(Executive Officer, Director)Philip S. Low(Director)Andrew Scharenberg(Founder)Michael Jensen(Founder)Philip Low(Founder)Ryan Crisman(Founder)
Board seatLuke Evnin· per SEC Form D
Co-investorsDCVC BioQiming Venture Partners USASoftBank GroupK2 HealthVenturesSoftBank Vision FundAlexandria+2 more
Frontier is a drug discovery company developing small-molecule covalent drugs aimed at previously undruggable protein targets across the proteome.
AI & Machine LearningBiotechSouth San Francisco, US
Chris Varma, Ph.D.(Executive Officer, Director)Chris Varma(Co-founder, Chairman and CEO)inJim Winkler(Executive Officer)Johannes Hermann, Ph.D.(Executive Officer)Kevin Webster(Executive Officer)inGregory Chow(Executive Officer)
Board seatLuke Evnin· per SEC Form D
Co-investorsBerkeley CatalystDCVC (Data Collective)Droia VenturesFelicis VenturesRA CapitalDCVC Bio+2 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
HotKnot Therapeutics, Inc.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.